NCT04724018View on ClinicalTrials.gov

Sacituzumab Govitecan Plus EV in Metastatic UC

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

October 1, 2025

Study Completion Date

May 1, 2026

Conditions
Urothelial CancerMetastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma of the Renal Pelvis and UreterBladder Cancer
Interventions
DRUG

Sacituzumab Govitecan (SG)

Intravenous infusion

DRUG

Enfortumab vedotin-ejfv (EV)

Intravenous infusion

DRUG

Pembrolizumab

Intravenous infusion

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER